A strain of Lactobacillus paracasei CCFM1224 that promotes host HA synthesis and its postbiotics
Through the targeting of HAS1, HAS2, and HAS3 mRNAs through C. paracetabolium paracetum CCFM1224 and its epigenetics, HA synthesis in multiple tissues was promoted, and the problem of insufficient HA synthesis in the prior art was solved, which significantly improved the HA level of the host and delayed the The aging process.
Patent Information
- Application Number
- CN202310075977.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-01-17
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2043-01-17
AI Technical Summary
The prior art is difficult to effectively promote the synthesis of hyaluronic acid (HA) in the body, resulting in joint stiffness and skin aging, and the existing methods have limited effect on the target screening of HA synthesis rate-limiting enzymes.
Using C. paracetaccium CCFM1224 and its epigenetics, the expression of HAS1, HAS2, and HAS3 mRNA is used to promote HA synthesis in intestinal, skin, joints and heart tissues, and prepare food, health products, medicines or cosmetics. product.
It significantly increased the HA levels in the host serum and tissues, promoted the HA synthesis of the skin, joints and hearts of aging mice, and delayed the aging process.
Smart Images

Figure CN116042480B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a Lactobacillus paracasei CCFM1224 capable of promoting a host to synthesize HA and a postbiotic thereof, and belongs to the technical field of microorganisms and the technical field of medicine. Background Art
[0002] Hyaluronic acid (HA) is a linear glycosaminoglycan with important physiological functions. With its unique molecular structure and physicochemical properties, it exhibits a variety of important physiological functions in the body, such as lubricating joints. Generally speaking, the body's HA begins to be lost at the age of 25, and the HA content at the age of 30 is often only 65% of that in childhood, and it decreases to 25% at the age of 60. As an important component of synovial fluid, the reduction of HA components in the joints makes the joints unable to absorb or disperse external impacts, and the joints become stiff, resulting in difficulty in walking. The reduction of HA in the joints is an important cause of osteoarthritis. Secondly, with the reduction of HA, the water content will reach a lower level, and the skin will lack elasticity and luster, showing wrinkles and aging. Therefore, increasing the HA content in the body is of great significance for protecting the health of the skin and joints and delaying the aging of the body.
[0003] At present, it has been reported that epidermal growth factor, transforming growth factor β, retinoic acid, N-methylserine, cytokines, and estradiol derivatives can be used to increase HA synthesis in cells (Journal of Investigative Dermatology.120(6),1038-1044, Journal of Biological Chemistry,276(23),20428-20435, Biochemical Journal,404,327-336, Circulation Research,94(5),592-600, Journal of Biological Chemistry,285(32),24639-24645.)
[0004] CN111902149A discloses a method for promoting HA synthesis, wherein a polysaccharide derivative or a salt thereof is brought into contact with hyaluronic acid producing cells, thereby promoting the synthesis of hyaluronic acid in the hyaluronic acid producing cells.
[0005] CN 113081878A discloses a composition for promoting skin HA synthesis, which comprises 0.01-5.0 parts by weight of L-lactic acid.
[0006] In mammals, HAS contains three isozymes: HAS1, HAS2 and HAS3. These HAS subtypes have similar structures and amino acid sequences, can catalyze the synthesis of HA, and are the rate-limiting enzymes in the HA synthesis process. The present invention targets the gene expression of the rate-limiting enzyme in the HA synthesis process, and specifically screens the postbiotics prepared by probiotics that can promote HA synthesis through cell experiments, and uses animal experiments to verify its promotion of HA synthesis and effect in vivo, proving that HAS1 mRNA, HAS2 mRNA and HAS3 mRNA are used as targets to screen substances that promote HA synthesis. Summary of the invention
[0007] The invention provides an application of a postbiotic of Lacticaseibacillus paracasei GDMCC No. 62272 in preparing a product for preventing and / or repairing dry skin and delaying aging.
[0008] The Lacticaseibacillus paracasei GDMCC No. 62272 is recorded in the Chinese invention patent application with publication number CN 114717146A and is named as Lacticaseibacillus paracasei CCFM1224.
[0009] In one embodiment of the present invention, the postbiotics include dead cells, fermentation supernatant, bacterial lysate and / or fermentation broth, or powders thereof prepared by any drying method.
[0010] In one embodiment of the present invention, the method for preparing the fermentation broth is to inoculate the Lactobacillus paracasei CCFM1224 into a fermentation medium to obtain the bacteria, and then heat-treat the obtained fermentation broth.
[0011] In one embodiment of the present invention, the heat treatment conditions are 60-95° C., 25-35 min.
[0012] In one embodiment of the present invention, the method for preparing the bacterial lysate is to inoculate the Lactobacillus paracasei CCFM1224 into a fermentation medium to obtain a bacterial solution, perform high-pressure homogenization, and centrifuge to obtain a bacterial lysate.
[0013] In one embodiment of the present invention, the Lactobacillus paracasei CCFM1224 is inoculated into a fermentation medium to obtain a bacterial solution, and the bacterial sludge is centrifuged to obtain a bacterial sludge precipitate, and the inactivated bacterial cells are obtained after heat treatment or freeze-drying;
[0014] In one embodiment of the present invention, the powder is a solid powder postbiotic prepared by spray drying, vacuum freeze drying, fluidized bed drying, and vacuum drying the prepared liquid postbiotic of Lactobacillus paracasei CCFM1224.
[0015] In one embodiment of the present invention, the product is food, health care product, medicine or cosmetics.
[0016] In one embodiment of the present invention, the medicine contains the postbiotic, a drug carrier and / or a pharmaceutical excipient.
[0017] In one embodiment of the present invention, the drug carrier comprises microcapsules, microspheres, nanoparticles and / or liposomes.
[0018] In one embodiment of the present invention, the dosage form of the drug comprises granules, capsules, tablets, pills or oral liquids.
[0019] In one embodiment of the present invention, the promotion of host HA synthesis mainly includes HA levels in tissues such as skin, joints, and heart.
[0020] In one embodiment of the present invention, the application method includes topical application and oral use.
[0021] In one embodiment of the present invention, the product includes food, health care products, medicines or cosmetics.
[0022] In one embodiment of the present invention, the food comprises the above-mentioned Lactobacillus paracasei CCFM1224 postbiotics and conventional auxiliary materials.
[0023] In one embodiment of the present invention, the conventional auxiliary materials include one or more of fillers, flavoring agents, binders, disintegrants, lubricants, antacids, and nutritional enhancers.
[0024] In one embodiment of the present invention, the health product comprises the above-mentioned Lactobacillus paracasei CCFM1224 postbiotic and conventional auxiliary materials.
[0025] In one embodiment of the present invention, the conventional auxiliary materials include one or more of fillers, flavoring agents, binders, disintegrants, lubricants, antacids, and nutritional enhancers.
[0026] In one embodiment of the present invention, the medicine comprises the above-mentioned Lacticaseibacillus paracasei CCFM1224 postbiotic, a drug carrier and / or a pharmaceutical excipient.
[0027] In one embodiment of the present invention, the pharmaceutical excipient comprises an excipient and an additive.
[0028] In one embodiment of the present invention, the pharmaceutical excipients include solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrators, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculating agents, filter aids and release retardants.
[0029] In one embodiment of the present invention, the cosmetic comprises the above-mentioned Lacticaseibacillus paracasei CCFM1224 postbiotic, matrix raw materials and / or conventional auxiliary materials.
[0030] In one embodiment of the present invention, the matrix raw materials include oil raw materials, wax raw materials, synthetic oil raw materials, powdery raw materials, colloid raw materials, coagulants, and surfactants.
[0031] In one embodiment of the present invention, the conventional auxiliary materials include one or more of moisturizers, whitening agents, flavoring agents, adhesives, lubricants, preservatives, film agents, antioxidants, emulsifiers and cosmetic nutritional additives.
[0032] The present invention also provides a product for preventing and / or repairing dry skin and delaying aging, wherein the product contains Lacticaseibacillus paracasei CCFM1224 and / or its postbiotics.
[0033] In one embodiment of the present invention, the product is food, health care product, medicine or cosmetics.
[0034] In one embodiment of the present invention, the postbiotics include dead cells, fermentation supernatant, bacterial lysate and / or fermentation broth, or powders thereof prepared by any drying method.
[0035] The present invention provides application of the above-mentioned Lacticaseibacillus paracasei CCFM1224 and / or its postbiotics in preparing a product for promoting host HA synthesis. The product comprises the above-mentioned Lacticaseibacillus paracasei CCFM1224 and / or its postbiotics.
[0036] In one embodiment of the present invention, the product comprises at least one of the following effects:
[0037] (1) Promote HA synthesis in intestinal cells (HT29);
[0038] (2) Promote HA synthesis in skin cells (HaCaT);
[0039] (3) Significantly increased serum HA levels in mice;
[0040] (4) Significantly promoted HA synthesis in the skin tissue of aged mice;
[0041] (5) Significantly promoted HA synthesis in the joint tissues of aged mice;
[0042] (6) Significantly increased HA levels in heart tissue of aged mice;
[0043] The present invention also provides a product for preventing and / or repairing dry skin and delaying aging, wherein the product contains Lacticaseibacillus paracasei CCFM1224 and / or its postbiotics.
[0044] In one embodiment of the present invention, in the product, the dosage of the postbiotics prepared by the above-mentioned Lacticaseibacillus paracasei CCFM1224 is not less than 60 mg / kg body weight.
[0045] In one embodiment of the present invention, the product comprises food, health care product, medicine or cosmetics.
[0046] In one embodiment of the present invention, the food comprises the above composition and conventional auxiliary materials.
[0047] In one embodiment of the present invention, the conventional auxiliary materials include one or more of fillers, flavoring agents, binders, disintegrants, lubricants, antacids, and nutritional enhancers.
[0048] In one embodiment of the present invention, the health care product comprises the above composition and conventional auxiliary materials.
[0049] In one embodiment of the present invention, the conventional auxiliary materials include one or more of fillers, flavoring agents, binders, disintegrants, lubricants, antacids, and nutritional enhancers.
[0050] In one embodiment of the present invention, the medicine comprises a composition, a drug carrier and / or a pharmaceutical excipient.
[0051] In one embodiment of the present invention, the drug carrier comprises microcapsules, microspheres, nanoparticles and liposomes.
[0052] In one embodiment of the present invention, the pharmaceutical excipient comprises an excipient and an additive.
[0053] In one embodiment of the present invention, the pharmaceutical excipients include solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrators, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculating agents, filter aids and release retardants.
[0054] In one embodiment of the present invention, the additive comprises microcrystalline cellulose, hydroxypropyl methylcellulose and refined lecithin.
[0055] In one embodiment of the present invention, the dosage form of the drug comprises granules, capsules, tablets, pills or oral liquids.
[0056] In one embodiment of the present invention, the cosmetic comprises the above composition, matrix raw materials and / or conventional auxiliary materials.
[0057] In one embodiment of the present invention, the matrix raw materials include oil raw materials, wax raw materials, synthetic oil raw materials, powdery raw materials, colloid raw materials, coagulants, and surfactants.
[0058] In one embodiment of the present invention, the conventional auxiliary materials include one or more of moisturizers, whitening agents, flavoring agents, adhesives, lubricants, preservatives, film agents, antioxidants, emulsifiers and cosmetic nutritional additives.
[0059] Beneficial Effects
[0060] The postbiotics prepared by Lacticaseibacillus paracasei CCFM1224 of the present invention have the ability to promote host HA synthesis both for external and oral use, which is specifically embodied in:
[0061] (1) Promote HA synthesis in intestinal cells (HT29);
[0062] (2) Promote HA synthesis in skin cells (HaCaT);
[0063] (3) Significantly increased serum HA levels in mice;
[0064] (4) Significantly promoted HA synthesis in the skin tissue of aged mice;
[0065] (5) Significantly promoted HA synthesis in the joint tissues of aged mice;
[0066] (6) Significantly increased HA levels in heart tissue of aged mice;
[0067] Therefore, Lacticaseibacillus paracasei CCFM1224 and the postbiotics prepared therefrom have great application prospects in the preparation of products that promote host HA synthesis. BRIEF DESCRIPTION OF THE DRAWINGS
[0068] Figure 1 : Effects of different postbiotics on HT29 cell proliferation.
[0069] Figure 2 :Effects of different postbiotics on the expression of HAS2 mRNA and HAS3 mRNA in HT29 cells.
[0070] Figure 3 :Effects of different postbiotics on the proliferation of HaCaT cells.
[0071] Figure 4 :Effects of different postbiotics on the expression of HAS1 mRNA and HAS2 mRNA in HaCaT cells.
[0072] Figure 5 : Flowchart of mouse experiments.
[0073] Figure 6 :Effects of different postbiotics on serum HA content in mice.
[0074] Figure 7 :Effects of different postbiotics on HA synthesis in mouse skin tissue.
[0075] Figure 8 :Effects of different postbiotics on HA synthesis in mouse joint tissue.
[0076] Fig. 9 :Effects of different postbiotics on HA content in mouse heart tissue.
[0077] “*” indicates statistical difference compared with the Model group (P<0.05), “**” indicates significant statistical difference compared with the Model group (P<0.01), and “***” indicates extremely significant statistical difference compared with the Model group (P<0.001). DETAILED DESCRIPTION
[0078] The human colon cancer cell line (HT29) and human immortalized keratinocytes (HaCaT) involved in the following examples were purchased from Shanghai Cell Bank.
[0079] The Lactobacillus plantarum 23 and Lactobacillus paracasei FXJWS3M2 involved in the following examples are from: Food Biotechnology Center Laboratory of Jiangnan University
[0080] The BALB / c mice involved in the following examples were purchased from Vital River Company.
[0081] The culture medium involved in the following examples is as follows:
[0082] MRS liquid culture medium: yeast powder 5.0 g / L, beef extract 10.0 g / L, peptone 10.0 g / L, glucose 20.0 g / L, anhydrous sodium acetate 2.0 g / L, diammonium hydrogen citrate 2.0 g / L, dipotassium hydrogen phosphate 2.6 g / L, manganese sulfate monohydrate 0.25 g / L, magnesium sulfate heptahydrate 0.5 g / L and Tween-80 1 mL / L, pH 6.2-6.4.
[0083] MRS solid culture medium: yeast powder 5.0 g / L, beef extract 10.0 g / L, peptone 10.0 g / L, glucose 20.0 g / L, anhydrous sodium acetate 2.0 g / L, diammonium hydrogen citrate 2.0 g / L, dipotassium hydrogen phosphate 2.6 g / L, manganese sulfate monohydrate 0.25 g / L, magnesium sulfate heptahydrate 0.5 g / L, Tween-80 1 mL / L and agar 20.0 g / L, pH 6.2-6.4.
[0084] Cell culture medium: 89% (v / v) DMEM medium + 10% (v / v) fetal bovine serum + 1% (v / v) 100× penicillin and streptomycin mixed solution (the penicillin content in the mixed solution is 10000 U / mL, and the streptomycin concentration is 10 mg / mL).
[0085] The present invention will be further described below in conjunction with specific embodiments.
[0086] Example 1: Cell recovery and culture
[0087] First, take out the frozen human colon cancer cell line (HT29) and human immortalized keratinocytes (HaCaT), quickly thaw them in a 37°C water bath, then centrifuge at 1000r / min for 3min, discard the supernatant, add an appropriate volume of cell culture medium to resuspend the cells, place them in a culture dish, and culture them in a 37°C incubator containing 5% CO2. When the cells regain vitality and grow for 1 to 2 days to reach 70% to 80% fusion, cell passage is performed.
[0088] Example 2: Preparation of postbiotics by Lactobacillus paracasei CCFM1224
[0089] (1) using MRS solid culture medium to culture in a water-tight constant temperature incubator at 37° C. for 24 to 48 hours to obtain a single colony; picking a single colony and inoculating it into MRS liquid culture medium, and culturing it at 37° C. for 12 to 18 hours to obtain culture solution 1;
[0090] The culture solution 1 was inoculated into MRS liquid medium at an inoculum volume of 2% (v / v), and cultured at 37°C for 12 h to obtain seed solution;
[0091] The seed solution was inoculated into MRS liquid medium at 3% to 5% (v / v) for expansion and cultured at 37°C for 18 to 24 hours to obtain bacterial solution with a bacterial concentration of 1.3×10 10 CFU / ml.
[0092] The bacterial liquid was heat treated (65°C, 30 min), and then high-pressure homogenized in a high-pressure homogenizer (800-1200 MPa, 3 times) to obtain a bacterial lysate, which was freeze-dried to obtain a postbiotic freeze-dried powder for use, thereby preparing the postbiotics of Lactobacillus paracasei CCFM1224.
[0093] (2) Prepare Lactobacillus plantarum 23 postbiotics and Lactobacillus paracasei FXJWS3M2 postbiotics according to the method of step (1).
[0094] Example 3: Effect of postbiotics prepared by Lactobacillus paracasei CCFM1224 on HT29 cell proliferation
[0095] The specific steps are as follows:
[0096] (1) Take 100 μl of HT29 cells in the logarithmic growth phase and add 5×10 5 The cells were inoculated into 96-well plates at a concentration of 10 cells / well, and the outermost circle was filled with PBS solution to prevent edge effect. After culturing for 24 hours to allow them to adhere to the plate, blank group, control group, and treatment group were set up.
[0097] The blank group contained only cell culture medium but no HT29 cells;
[0098] The control group contained both cell culture medium and HT29 cells but no postbiotics;
[0099] The treatment group was treated with cell culture medium to resuspend the postbiotics (the amount of postbiotics after resuspending was the same as that of fermentation to a concentration of 1.0×10 7 CFU / ml of bacterial solution): 100 μl of Lactobacillus paracasei CCFM1224 postbiotics and postbiotics prepared by Lactobacillus plantarum 23 were added to the wells containing HT29 cells respectively;
[0100] (2) Incubate each group of well plates in an incubator at 37°C for 4 h. After incubation, add 10 μl of CCK8 solution to each well and incubate for 2 h, then measure the absorbance (OD) at 450 nm.
[0101] The cell proliferation rate was calculated according to the following formula: cell proliferation rate (%) = (OD value of treatment group - OD value of blank group) / (OD value of control group - OD value of blank group) × 100%.
[0102] Effects on cell proliferation Figure 1 As shown: Compared with the control group (100%), the postbiotics prepared by Lactobacillus paracasei CCFM1224 after resuspension were equivalent to 1.0×10 7 CFU / ml of bacterial components had no inhibitory effect on the proliferation of HT29 cells, and its cell viability was 109%. It can be selected as a suitable postbiotic concentration for subsequent cell experiments. The postbiotic concentration of Lactobacillus plantarum postbiotic 23 after resuspension is equivalent to 1.0×10 7 CFU / ml of bacterial components had no inhibitory effect on the proliferation of HT29 cells, and the cell viability was 101%, which can be selected as a suitable postbiotic concentration for subsequent cell experiments.
[0103] Example 4: Effect of postbiotics prepared by Lactobacillus paracasei CCFM1224 on the expression of HAS2 mRNA and HAS3 mRNA in HT29 cells
[0104] The specific steps are as follows:
[0105] (1) HT29 cells were cultured at 2.5×10 6 Cells were inoculated with 100 μg / ml on a 12-well plate and cultured overnight until the cells adhered to the wall. The old culture medium was discarded and the cells were rinsed with PBS three times. The control group and the treatment group were set up.
[0106] The control group, without postbiotics, contained only HT29 cells and cell culture medium;
[0107] The treatment group was composed of postbiotics prepared by Lactobacillus paracasei CCFM1224 and Lactobacillus plantarum 23. The postbiotics were resuspended in cell culture medium (the amount of postbiotics after resuspending was the same as that of the fermented postbiotics to a concentration of 1.0×10 7 CFU / ml of bacterial solution was equivalent to the amount of postbiotics prepared): 2 ml of postbiotics prepared by Lactobacillus paracasei CCFM1224 and Lactobacillus plantarum 23 were added to the wells containing HT29 cells in 12-well plates;
[0108] The above-mentioned groups of well plates were incubated in an incubator at 37° C. for 4 h, with three parallels for each sample.
[0109] (2) After the co-culture of postbiotics and cells was completed, the culture supernatant was discarded, each well was quickly washed three times with PBS, 1 mL of cell lysis solution was added to each well, and the well was repeatedly blown and vortexed. The cell lysis solution was aspirated to extract RNA, and reverse transcribed into cDNA using an RT-PCR reverse transcription kit. The expression of genes in HT29 cells was detected by real-time fluorescence quantitative method. -△△Ct The expression of HAS2 mRNA and HAS3 mRNA was calculated by the formula, wherein the internal reference was GAPDH, and the primers were described in Table 1 below. The results are shown in Table 1. Figure 2 shown.
[0110] Table 1: Primer sequences
[0111] Oligo Name sequence describe F-qPCR-hHAS2 TCCTGGATCTCATTCCTCAGC Hyaluronan synthase 2 (HAS2) R-qPCR-hHAS2 TGCACTGAACACACCCAAAATA Hyaluronan synthase 2 (HAS2) F-qPCR-hHAS3 GAGATGTCCAGATCCTCAACAA Hyaluronan synthase 3 (HAS3) R-qPCR-hHAS3 CCCACTAATACACTGCACAC Hyaluronan synthase 3 (HAS3)
[0112] Depend on Figure 2 It can be seen that compared with the control group, the postbiotics prepared by Lactobacillus paracasei CCFM1224 significantly promoted the expression of HAS2 mRNA and HAS3 mRNA in HT29 cells.
[0113] The experimental results show that, with the expression level of the control group as 1, the postbiotics prepared by Lactobacillus paracasei CCFM1224 can upregulate the expression of HAS2 mRNA and HAS3 mRNA in HT29 cells, with relative expression levels of 5.75 and 1.78, respectively. Compared with the control group, the relative expression levels of HAS2 mRNA and HAS3 mRNA of Lactobacillus plantarum 23 were 1.13 and 0.67, respectively, and their expression was not upregulated. Moreover, the postbiotics prepared by Lactobacillus paracasei 1224 increased the expression of HAS2 mRNA by more than 4 times compared with Lactobacillus plantarum 23.
[0114] HAS2 and HAS3 are both HA synthases. On the cytoplasmic membrane, the two precursors of HA, UDP-GlcA and UDP-GlcNAc, are alternately linked into linear glycosaminoglycans through β-1,3 and β-1,4 glycosidic bonds. Their expression can affect the level of HA in cells. Therefore, the postbiotics prepared by Lactobacillus paracasei CCFM1224 increase the synthesis of HA by promoting the expression of HAS2 mRNA and HAS3 mRNA in the intestine.
[0115] Example 5: Effect of postbiotics prepared by Lactobacillus paracasei CCFM1224 on the proliferation of HaCaT cells
[0116] The specific steps are as follows:
[0117] (1) Take 100 μl of HaCaT cells in the logarithmic growth phase and add 5×10 5 The cells were inoculated into 96-well plates at a concentration of 10 cells / well, and the outermost circle was filled with PBS solution to prevent edge effect. After culturing for 24 hours to allow them to adhere to the plate, blank group, control group and treatment group were set up.
[0118] The blank group contained only cell culture medium without HaCaT cells;
[0119] The control group contained both cell culture medium and HaCaT cells without postbiotics;
[0120] The treatment group was treated with cell culture medium to resuspend the postbiotics (the amount of postbiotics after resuspending was the same as that of fermentation to a concentration of 1.0×10 7 CFU / ml of bacterial solution was equivalent to the amount of postbiotics prepared): 100 μl of Lactobacillus paracasei CCFM1224 postbiotics and Lactobacillus paracasei FXJWS3M2 postbiotics were added to the wells containing HaCaT cells respectively;
[0121] (2) The above-mentioned well plates were incubated in a 37°C incubator for 4 h. After the incubation, 10 μl of CCK8 solution was added to each well and incubated for 2 h, and the absorbance (OD) at 450 nm was measured.
[0122] The cell proliferation rate was calculated according to the following formula: cell proliferation rate (%) = (OD value of treatment group - OD value of blank group) / (OD value of control group - OD value of blank group) × 100%.
[0123] Effects on cell proliferation Figure 3 As shown in Figure 2, compared with the control group (cell viability 99%), the postbiotics prepared by Lactobacillus paracasei CCFM1224 (cell viability 125%) and the postbiotics prepared by Lactobacillus paracasei FXJWS3M2 (cell viability 116%) were significantly higher than those prepared by the control group (cell viability 99%) at a concentration of 1.0×10 7CFU / ml does not affect the proliferation of HaCaT cells and can be selected as an appropriate postbiotic concentration for subsequent cell experiments.
[0124] Example 6: Effects of postbiotics prepared by Lactobacillus paracasei CCFM1224 on HAS1 mRNA and HAS2 mRNA in HaCaT cells
[0125] The specific steps are as follows:
[0126] (1) HaCaT cells were cultured at 2.5×10 6 Cells were inoculated with 100 μg / ml on a 12-well plate and cultured overnight until the cells adhered to the wall. The old culture medium was discarded and the cells were rinsed with PBS three times. The control group and the treatment group were set up.
[0127] The control group was a group containing only HaCaT cells but not postbiotics;
[0128] The treatment groups were postbiotics prepared by Lactobacillus paracasei CCFM1224 and Lactobacillus paracasei FXJWS3M2, and the postbiotics were resuspended in cell culture medium (the amount of postbiotics after resuspending was the same as that of fermentation to a concentration of 1.0×10 7 CFU / ml of bacterial liquid was equivalent to the amount of postbiotics prepared, and 2 ml of postbiotics prepared by Lactobacillus paracasei 1224 and Lactobacillus paracasei FXJWS3M2 were added to a 12-well plate respectively and cultured for 4 h, with three replicates for each sample.
[0129] (2) After the co-culture of postbiotics and cells was completed, the culture supernatant was discarded, each well was quickly washed three times with PBS, 1 mL of cell lysis solution was added to each well, and the well was repeatedly blown and vortexed. The cell lysis solution was aspirated to extract RNA, and reverse transcribed into cDNA using an RT-PCR reverse transcription kit. The expression of genes in HaCaT cells was detected by real-time fluorescence quantitative method. -△△Ct The expression levels of HAS1 mRNA and HAS2 mRNA were calculated using the formula, wherein the internal reference was GAPDH, and the primers were described in Table 2 below. The results are shown in Table 2. Figure 4 shown.
[0130] Table 2: Primer sequences
[0131] Oligo Name sequence describe F-qPCR-hHAS1 GAGCCTCTTCGCGTACCTG Hyaluronan synthase 1 (HAS1) R-qPCR-hHAS1 CCTCCTGGTAGGCGGAGAT Hyaluronan synthase 1 (HAS1) F-qPCR-hHAS2 TCCTGGATCTCATTCCTCAGC Hyaluronan synthase 2 (HAS2) R-qPCR-hHAS2 TGCACTGAACACACCCAAAATA Hyaluronan synthase 2 (HAS2)
[0132] The results show that Figure 4It can be seen that, with the expression level of the control group as 1, the postbiotics prepared by Lactobacillus paracasei CCFM1224 significantly promoted the expression of HAS1 mRNA and HAS2 mRNA in HaCaT cells, with relative expression levels of 1.55 and 4.54, respectively. After intervention with postbiotics prepared by Lactobacillus paracasei FXJWS3M2, the relative expression levels of HAS1 mRNA and HAS2 mRNA were 0.33 and 0.68, respectively, which did not promote the expression of HAS1 mRNA and HAS2 mRNA compared with the control group.
[0133] The experimental results show that the postbiotics prepared by Lactobacillus paracasei CCFM1224 can upregulate the expression of HAS1 mRNA and HAS2 mRNA in HaCaT cells.
[0134] HAS1 and HAS2 are two isozymes of HA synthase. On the cytoplasmic membrane, they alternately connect the two precursors of HA, UDP-GlcA and UDP-GlcNAc, into linear glycosaminoglycans through β-1,3 and β-1,4 glycosidic bonds. Their expression can affect the level of HA in cells.
[0135] It can be said that the postbiotics prepared by Lactobacillus paracasei CCFM1224 increase the synthesis of HA in skin cells by promoting the expression of HAS1 mRNA and HAS2 mRNA.
[0136] Example 7: Effects of Lactobacillus paracasei CCFM1224 and postbiotics prepared therefrom on serum HA levels in aged mice
[0137] The preparation method of the live bacteria of Lactobacillus paracasei CCFM1224 involved in the following embodiments is the same as that in Example 2, wherein the bacterial solution is obtained and then centrifuged to collect the bacterial mud without heat treatment and high-pressure homogenization; the preparation method of the live bacteria of Lactobacillus plantarum FXJWS3M2 and Lactobacillus plantarum 23 is the same as that of Lactobacillus paracasei CCFM1224.
[0138] The specific steps are as follows:
[0139] (1) 45 healthy male BALB / c mice aged 8 weeks were randomly divided into 9 cages, with 5 mice in each cage. The 9 cages were as follows: except for the model group (Model), which had 2 cages, the other groups had 1 cage each, which were:
[0140] Blank group (Control): Use normal saline as control;
[0141] CCFM1224-L group: Live Lactobacillus paracasei CCFM1224 was used at a dose of 5×10 9 CFU / kg mouse body weight;
[0142] CCFM1224-D group: Lactobacillus paracasei CCFM1224 postbiotics were used at a dose of 500 mg / kg mouse body weight;
[0143] 23-L group: Lactobacillus plantarum 23 live bacteria, dose: 5×10 9 CFU / kg mouse body weight;
[0144] Group 23-D: Lactobacillus plantarum 23 postbiotics, dose: 500 mg / kg mouse body weight;
[0145] 3M2-L group: live bacteria of P. casei FXJWS3M2 were used at a dose of 5×10 9 CFU / kg mouse body weight;
[0146] 3M2-D group: FXJWS3M2 postbiotics were used at a dose of 500 mg / kg mouse body weight;
[0147] Among them, the postbiotics in the above groups are postbiotics prepared from the bacterial liquid fermented with the corresponding amount of live bacteria.
[0148] The experiment lasted for 9 weeks: After the mice adapted for one week, except for the blank group, the other groups were subcutaneously injected with D-galactose (500 mg / kg) at a rate of 0.2 mL / mouse / day. From the second week, the mice in each intervention group were gavaged with lyophilized powder of the corresponding strain or lyophilized powder of postbiotics prepared from the strain (dissolved in normal saline at the corresponding dose) at a rate of 0.2 mL / mouse / day; the blank group and the model group were gavaged with the same amount of normal saline as a control until the end of the experiment. All groups had free access to water and food. The experimental process is as follows Figure 5 shown.
[0149] After the experiment, the mice were anesthetized, and the eyeballs were removed to collect blood. The blood was kept at room temperature for 30 minutes. After the whole blood was stratified, it was centrifuged at 3500r / min for 10 minutes, and the upper serum was collected. The HA content of the serum was detected by ELISA HA kit. The results are as follows Figure 6 shown.
[0150] The results show that through Figure 6 It can be seen that compared with the blank group (HA content of 50.93 ng / ml), the HA content of the model group (26.55 ng / ml) was significantly reduced. After oral administration of live Lactobacillus paracasei CCFM1224 and postbiotics prepared therefrom, the serum HA contents were 37.22 ng / ml and 37.93 ng / ml, respectively, which were 21.95% and 24.28% higher than those of Lactobacillus paracasei FXJWS3M2 (other groups with higher HA content, with a value of 30.52 ng / ml), respectively, significantly increasing the serum HA level of the skin of aging mice.
[0151] Through the combined results of cell experiments and animal experiments, it can be seen that the postbiotics prepared by Lactobacillus paracasei CCFM1224, which can promote the expression of HAS1 mRNA, HAS2 mRNA, and HAS3 mRNA in HT29 cells and HaCaT cells, increased the HA content in the serum of aged mice in the oral animal experiment, indicating that Lactobacillus paracasei CCFM1224 and the postbiotics prepared therefrom can promote the host's HA synthesis.
[0152] Example 8: Effects of Lactobacillus paracasei CCFM1224 and postbiotics prepared therefrom on HA synthesis in the skin of aged mice
[0153] The preparation method of the live bacteria of Lactobacillus paracasei CCFM1224 involved in the following embodiments is the same as that in Example 2, wherein the bacterial solution is obtained and then centrifuged to collect the bacterial mud without heat treatment and high-pressure homogenization; the preparation method of the live bacteria of Lactobacillus plantarum FXJWS3M2 and Lactobacillus plantarum 23 is the same as that of Lactobacillus paracasei CCFM1224.
[0154] The specific steps are as follows:
[0155] (1) 45 healthy male BALB / c mice aged 8 weeks were randomly divided into 9 cages, with 5 mice in each cage. The 9 cages were as follows: except for the model group (Model), which had 2 cages, the other groups had 1 cage each, which were:
[0156] Blank group (Control): Use normal saline as control;
[0157] CCFM1224-L group: Live Lactobacillus paracasei CCFM1224 was used at a dose of 5×10 9 CFU / kg mouse body weight;
[0158] CCFM1224-D group: Lactobacillus paracasei CCFM1224 postbiotics were used at a dose of 500 mg / kg mouse body weight;
[0159] 23-L group: Lactobacillus plantarum 23 live bacteria, dose: 5×10 9 CFU / kg mouse body weight;
[0160] Group 23-D: Lactobacillus plantarum 23 postbiotics, dose: 500 mg / kg mouse body weight;
[0161] 3M2-L group: live bacteria of P. casei FXJWS3M2 were used at a dose of 5×10 9 CFU / kg mouse body weight;
[0162] 3M2-D group: FXJWS3M2 postbiotics were used at a dose of 500 mg / kg mouse body weight;
[0163] Among them, the postbiotics in the above groups are postbiotics prepared from the bacterial liquid fermented with the corresponding amount of live bacteria.
[0164] The experiment lasted for 9 weeks: After the mice adapted for one week, except for the blank group, the other groups were subcutaneously injected with D-galactose (500 mg / kg) at a rate of 0.2 mL / mouse / day. From the second week, the mice in each intervention group were gavaged with lyophilized powder of the corresponding strain or lyophilized powder of postbiotics prepared from the strain (dissolved in normal saline at the corresponding dose) at a rate of 0.2 mL / mouse / day; the blank group and the model group were gavaged with the same amount of normal saline as a control until the end of the experiment. All groups had free access to water and food. The experimental process is as follows Figure 5 shown.
[0165] After the experiment, the mice were killed, and the skin tissues on the back of the mice were cut to detect the gene expression levels of HA synthases HAS1, HAS2, and HAS3 in the skin tissues. The internal reference was mouse GAPDH, and the primers were described in Table 3. In addition, a homogenate was prepared at a weight-to-volume ratio of 1:10 with PBS, and the HA content of the skin was detected by an ELISA HA kit. The results are shown in Table 3. Figure 7 shown.
[0166] Table 3: Primer sequences
[0167]
[0168]
[0169] The results show that through Figure 7 It can be seen that, with the expression level of the model group as 1, oral administration of live bacteria of Lactobacillus paracasei CCFM1224 and the postbiotics prepared from them significantly promoted the expression of HAS1 mRNA, HAS2 mRNA, and HAS3 mRNA in skin tissue. The relative expression levels of HAS1 mRNA, HAS2 mRNA, and HAS3 mRNA in the live bacteria group of Lactobacillus paracasei CCFM1224 were 1.65, 2.80, and 1.72, respectively; the relative expression levels of the postbiotic group were 1.63, 7.33, and 2.21, respectively. The relative expression levels of HAS1 mRNA, HAS2 mRNA, and HAS3 mRNA in other live bacteria postbiotic groups were not increased compared with the model group.
[0170] In terms of the effect on skin HA content, compared with the blank group (HA content 7.89 ng / mg), the HA content of the model group was significantly reduced to 6.24 ng / mg skin tissue. Oral administration of live Lactobacillus paracasei CCFM1224 and postbiotics prepared from it significantly increased the HA content to 7.33 ng / mg and 7.90 ng / mg, respectively, which was 16.72% and 25.80% higher than the postbiotic FXJWS3M2 (the group with higher HA content increase, with a value of 6.28 ng / mg).
[0171] Through the combined results of cell experiments and animal experiments, it can be seen that the postbiotics prepared by Lactobacillus paracasei CCFM1224, which can promote the expression of HAS1 mRNA, HAS2 mRNA and HAS3 mRNA in HT29 cells and HaCaT cells, promoted the HA synthesis in aging mice in oral animal experiments, indicating that Lactobacillus paracasei CCFM1224 and the postbiotics prepared therefrom promote the synthesis of HA by upregulating the expression of HAS1 mRNA, HAS2 mRNA and HAS3 mRNA.
[0172] Example 9: Effects of Lactobacillus paracasei CCFM1224 and postbiotics prepared therefrom on HA synthesis in joints of aged mice
[0173] The preparation method of the live bacteria of Lactobacillus paracasei CCFM1224 involved in the following embodiments is the same as that in Example 2, wherein the bacterial solution is obtained and then centrifuged to collect the bacterial mud without heat treatment and high-pressure homogenization; the preparation method of the live bacteria of Lactobacillus plantarum FXJWS3M2 and Lactobacillus plantarum 23 is the same as that of Lactobacillus paracasei CCFM1224.
[0174] The specific steps are as follows:
[0175] (1) 45 healthy male BALB / c mice aged 8 weeks were randomly divided into 9 cages, with 5 mice in each cage. The 9 cages were as follows: except for the model group (Model), which had 2 cages, the other groups had 1 cage each, which were:
[0176] Blank group (Control): Use normal saline as control;
[0177] CCFM1224-L group: Live Lactobacillus paracasei CCFM1224 was used at a dose of 5×10 9 CFU / kg mouse body weight;
[0178] CCFM1224-D group: Lactobacillus paracasei CCFM1224 postbiotics were used at a dose of 500 mg / kg mouse body weight;
[0179] 23-L group: Lactobacillus plantarum 23 live bacteria, dose: 5×10 9CFU / kg mouse body weight;
[0180] Group 23-D: Lactobacillus plantarum 23 postbiotics, dose: 500 mg / kg mouse body weight;
[0181] 3M2-L group: live bacteria of P. casei FXJWS3M2 were used at a dose of 5×10 9 CFU / kg mouse body weight;
[0182] 3M2-D group: FXJWS3M2 postbiotics were used at a dose of 500 mg / kg mouse body weight;
[0183] Among them, the postbiotics in the above groups are postbiotics prepared from the bacterial liquid fermented with the corresponding amount of live bacteria.
[0184] The experiment lasted for 9 weeks: After the mice adapted for one week, except for the blank group, the other groups were subcutaneously injected with D-galactose (500 mg / kg) at a rate of 0.2 mL / mouse / day. From the second week, the mice in each intervention group were gavaged with lyophilized powder of the corresponding strain or lyophilized powder of postbiotics prepared from the strain (dissolved in normal saline at the corresponding dose) at a rate of 0.2 mL / mouse / day; the blank group and the model group were gavaged with the same amount of normal saline as a control until the end of the experiment. All groups had free access to water and food. The experimental process is as follows Figure 5 shown.
[0185] After the experiment, the mice were killed, and the joint tissues of the mice were cut to detect the gene expression levels of HA synthase HAS1, HAS2, and HAS3 in the skin tissues. The internal reference was mouse GAPDH, and the primers were described in Table 4. The homogenate was prepared at a weight-to-volume ratio of 1:6 with PBS, and the HA content of the joints was detected by ELISA HA kit. The results are shown in Figure 8 shown.
[0186] Table 4: Primer sequences
[0187] Oligo Name sequence describe F-qPCR-hHAS1 GGCGAGCACTCACGATCATC Hyaluronan synthase 1 (HAS1) R-qPCR-hHAS1 AGGAGTCCATAGCGATCTGAAG Hyaluronan synthase 1 (HAS1) F-qPCR-hHAS2 TGTGAGAGGTTTCTATGTGTCCT Hyaluronan synthase 2 (HAS2) R-qPCR-hHAS2 ACCGTACAGTCCAAATGAGAAGT Hyaluronan synthase 2 (HAS2) F-qPCR-hHAS3 CCTGGAGCACCGTCGAATG Hyaluronan synthase 3 (HAS3) R-qPCR-hHAS3 CCTTGAGGTTTGGAAAGGCAA Hyaluronan synthase 3 (HAS3)
[0188] The results show that through Figure 8It can be seen that, with the expression level of the model group as 1, oral administration of live bacteria of Lactobacillus paracasei CCFM1224 and the postbiotics prepared from them significantly promoted the expression of HAS1 mRNA, HAS2 mRNA, and HAS3 mRNA in joint tissues, among which the relative expression levels of HAS1 mRNA, HAS2 mRNA, and HAS3 mRNA in the live bacteria group of Lactobacillus paracasei CCFM1224 were 2.40, 3.59, and 1.85, respectively; and the relative expression levels of the postbiotic group were 2.50, 4.15, and 1.80, respectively. The relative expression levels of HAS1 mRNA, HAS2 mRNA, and HAS3 mRNA in other live bacteria postbiotic groups were not increased compared with the model group.
[0189] In terms of the effect on the HA content in the joints, compared with the blank group (HA content 0.91 ng / mg), the HA content in the model group was significantly reduced to 0.70 ng / mg of joint tissue. Oral administration of live Lactobacillus paracasei CCFM1224 and postbiotics prepared from it significantly increased the HA content, which were 0.90 ng / mg and 0.93 ng / mg, respectively, which were 16.88% and 20.78% higher than the postbiotic FXJWS3M2 (the group with higher HA content increase, with a value of 0.77 ng / mg).
[0190] Through the combined results of cell experiments and animal experiments, it can be seen that the postbiotics prepared by Lactobacillus paracasei CCFM1224, which can promote the expression of HAS1 mRNA, HAS2 mRNA and HAS3 mRNA in HT29 cells and HaCaT cells, promoted the HA synthesis in aging mice in oral animal experiments, indicating that Lactobacillus paracasei CCFM1224 and the postbiotics prepared therefrom promote the synthesis of HA by upregulating the expression of HAS1 mRNA, HAS2 mRNA and HAS3 mRNA.
[0191] Example 10: Effects of Lactobacillus paracasei CCFM1224 and postbiotics prepared therefrom on HA content in the hearts of aged mice
[0192] The preparation method of the live bacteria of Lactobacillus paracasei CCFM1224 involved in the following embodiments is the same as that in Example 2, wherein the bacterial solution is obtained and then centrifuged to collect the bacterial mud without heat treatment and high-pressure homogenization; the preparation method of the live bacteria of Lactobacillus plantarum FXJWS3M2 and Lactobacillus plantarum 23 is the same as that of Lactobacillus paracasei CCFM1224.
[0193] The specific steps are as follows:
[0194] (1) 45 healthy male BALB / c mice aged 8 weeks were randomly divided into 9 cages, with 5 mice in each cage. The 9 cages were as follows: except for the model group (Model), which had 2 cages, the other groups had 1 cage each, which were:
[0195] Blank group (Control): Use normal saline as control;
[0196] CCFM1224-L group: Live Lactobacillus paracasei CCFM1224 was used at a dose of 5×10 9 CFU / kg mouse body weight;
[0197] CCFM1224-D group: Lactobacillus paracasei CCFM1224 postbiotics were used at a dose of 500 mg / kg mouse body weight;
[0198] 23-L group: Lactobacillus plantarum 23 live bacteria, dose: 5×10 9 CFU / kg mouse body weight;
[0199] Group 23-D: Lactobacillus plantarum 23 postbiotics, dose: 500 mg / kg mouse body weight;
[0200] 3M2-L group: live bacteria of P. casei FXJWS3M2 were used at a dose of 5×10 9 CFU / kg mouse body weight;
[0201] 3M2-D group: FXJWS3M2 postbiotics were used at a dose of 500 mg / kg mouse body weight;
[0202] Among them, the postbiotics in the above groups are postbiotics prepared from the bacterial liquid fermented with the corresponding amount of live bacteria.
[0203] The experiment lasted for 9 weeks: After the mice adapted for one week, except for the blank group, the other groups were subcutaneously injected with D-galactose (500 mg / kg) at a rate of 0.2 mL / mouse / day. From the second week, the mice in each intervention group were gavaged with lyophilized powder of the corresponding strain or lyophilized powder of postbiotics prepared from the strain (dissolved in normal saline at the corresponding dose) at a rate of 0.2 mL / mouse / day; the blank group and the model group were gavaged with the same amount of normal saline as a control until the end of the experiment. All groups had free access to water and food. The experimental process is as follows Figure 5 shown.
[0204] After the experiment, the mice were killed, and the heart tissues were removed and homogenized with PBS at a weight-volume ratio of 1:3. The HA content of the heart was detected by ELISA HA kit. The results are as follows: Fig. 9 shown.
[0205] The results show that through Fig. 9It can be seen that compared with the blank group (HA content 0.64ng / mg), the HA content in the model group was significantly reduced to 0.49ng / mg heart tissue. Oral administration of live Lactobacillus paracasei CCFM1224 and postbiotics prepared from it significantly increased the HA content, which were 0.60ng / mg and 0.62ng / mg, respectively, which were 15.38% and 19.23% higher than Lactobacillus plantarum 23 (the group with higher HA content increase, with a value of 0.52ng / mg).
[0206] The results of cell experiments and animal experiments showed that the postbiotics prepared by Lactobacillus paracasei CCFM1224, which can promote the expression of HAS1 mRNA, HAS2 mRNA and HAS3 mRNA in HT29 cells and HaCaT cells, promoted the synthesis of HA in the skin, joints and hearts of aged mice in oral animal experiments, indicating that Lactobacillus paracasei CCFM1224 and the postbiotics prepared from it promoted the synthesis of host HA by upregulating the expression of HAS1 mRNA, HAS2 mRNA and HAS3 mRNA.
[0207] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.
Claims
1. A Lactobacillus paracasei ( Lacticaseibacillus paracasei ) Use of GDMCC No. 62272 and its postbiotics in the preparation of a drug for promoting host hyaluronic acid synthesis, characterized in that: The medicament is used to prevent and / or repair dry skin.
2. The use according to claim 1, characterized in that: The postbiotics are dead cells, fermentation supernatant and / or bacterial lysate, or powders prepared by any drying method.
3. The use according to claim 2, characterized in that: The preparation method of the postbiotics comprises the following steps: inoculating Lactobacillus paracasei GDMCC No. 62272 into a fermentation medium to obtain a bacterial liquid, and then subjecting the bacterial liquid to heat treatment and homogenization lysis to obtain the postbiotics.
4. The use according to claim 3, characterized in that: The medicine contains the postbiotics, as well as a drug carrier or a pharmaceutical excipient.
5. The use according to claim 4, characterized in that: The drug carrier is a microcapsule, a microsphere, a nanoparticle or a liposome.
6. The use according to claim 5, characterized in that: The dosage form of the medicine is granules, capsules, tablets, pills or oral liquid.
7. Lactobacillus paracasei ( Lacticaseibacillus paracasei ) GDMCC No. 62272 Application of postbiotics in the preparation of cosmetics for promoting the synthesis of hyaluronic acid in the host, characterized in that: The cosmetic is used to prevent and / or repair dry skin.
8. The use according to claim 7, characterized in that: The postbiotics are dead cells, fermentation supernatant and / or bacterial lysate, or powders prepared by any drying method.
9. The use according to claim 7, characterized in that: The preparation method of the postbiotics comprises the following steps: inoculating Lactobacillus paracasei GDMCC No. 62272 into a fermentation medium to obtain a bacterial liquid, and then subjecting the bacterial liquid to heat treatment and homogenization lysis to obtain the postbiotics.
Citation Information
Patent Citations
Hyaluronic acid synthesis promoter, method for promoting hyaluronic acid synthesis, and cell evaluation method
CN111902149A
Composition for synergistically promoting synthesis of hyaluronic acid in skin and application
CN113081878A
Fatty liver and obesity relieving metaplasm prepared from lactobacillus paracasei and application of fatty liver and obesity relieving metaplasm prepared from lactobacillus paracasei
CN114717146A
Lactobacillus paracasei capable of inhibiting abnormal proliferation of HaCaT cells
CN112094784A
Lactobacillus paracasei and application of lactobacillus paracasei in preparation of product for regulating skin microecosystem
CN114645001A
Cited By
Lactobacillus paracasei for converting truffle to generate various active small molecules, regulating and controlling collagen synthesis of skin cells and resisting aging
CN121294237A
